Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2025 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2025 Earnings Call Transcript October 29, 2025Fulcrum Therapeutics, Inc. misses on earnings expectations.
Fulcrum Therapeutics Inc. (FULC)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 26,881 | $247,305 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.35 | 43,360 | $492,027.60 | 43,360 | 2024-03-04 | Filing | |
| $13.00 | 1,923,076 | $24,999,988.00 | 11,609,704 | 2023-01-20 | Filing | |
| $7.80 | 58,369 | $455,091.42 | 9,686,628 | 2023-01-04 | Filing | |
| $7.03 | 122,334 | $859,714.42 | 9,628,259 | 2023-01-04 | Filing | |
| $5.99 | 4,089 | $24,509.87 | 9,505,925 | 2022-12-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.06 | 498 | $2,519.88 | 14,062 | 2025-05-08 | Filing | |
| $7.76 | 236 | $1,831.36 | 11,571 | 2024-05-07 | Filing | |
| $11.72 | 4,884 | $57,218.50 | 11,807 | 2024-03-08 | Filing | |
| $3.31 | 210 | $695.10 | 15,992 | 2023-05-10 | Filing | |
| $15.00 | 6,766 | $101,490.00 | 499,864 | 2023-01-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 102,470 | $942,724 | 0.07% | |
| 2. | 83,234 | $765,753 | 0.01% | |
| 3. | 77,900 | $716,680 | 0% | |
| 4. | 30,041 | $276,377 | 0.01% | |
| 5. | 18,630 | $171,396 | 0.08% |
News See All
Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory
We came across a bullish thesis on Fulcrum Therapeutics, Inc. (FULC) on Stock Pursuit’s Substack. In this article, we will summarize the bulls’ thesis on FULC. Fulcrum Therapeutics, Inc.
Leerink Partners Upgrades Fulcrum Therapeutics, Inc. (FULC) to Outperform, Raises Price Target
On May 1, Fulcrum Therapeutics, Inc. (NASDAQ:FULC) provided business updates and reported results for the first quarter of fiscal 2025.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Call Transcript February 25, 2025Fulcrum Therapeutics, Inc. misses on earnings expectations.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter 2024 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2024 Earnings Call Transcript
Operator: Good morning and welcome to Fulcrum's Therapeutics Second Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions].
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2024 Earnings Call Transcript
Operator: Good morning and welcome to Fulcrum Therapeutics' First Quarter 2024 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript
Fulcrum Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.4, expectations were $-0.44.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2023 Earnings Call Transcript
Operator: Good morning and welcome to Fulcrum Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Fulcrum Therapeutics Second Quarter 2023 Financial Results and Business Update Conference Call. Currently all participants are in a listen-only mode.
Hedge Fund Resource Center Billionaire Hedge Funds
